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ABSTRACT 
Spasticity is an entity with which physical therapists are quite frequently 
faced. It is a common phenomenon among individuals who have sustained 
central nervous system damage. Spasticity is "associated with a wide variety of 
neurological diagnoses and may have benefits as well as negative qualities. 
The negative effects can lead to multiple complications which interfere with 
functions of every day living. Management of spasticity becomes necessary 
when it ~causes complication.s or interferes with function. There are several 
modes of intervention, including conservative physical therapy approaches 
and/or medical approaches. 
The purpose of this independent study is to review two medical methods of 
intervention: pharmacological treatment and dorsal rhizotomy. 
Pharmacological treatments include medications or local injections of various 
agents. These treatments only provide temporary relief unless they are 
conlLnued and/or repeated. Although pharmacological treatments have been 
found to be effective to reduce spasticity, they may have unwanted side effects. 
Dors~1 rhizotomies have been successful for reducing spasticity in appropriate 
\ ." 
candidates. The effects of this treatment are permanent and irreversible. Side 
VJ.J. 
effects are often temporary, such as sensory loss or muscle weakness, and 
there are risks related to surgery and anaesthesia. 
1\ 
., 
, , 
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CHAPTER 1 
INTRODUCTION 
Spasticity is a common phenomenon among individuals who have 
sustained some type of insult to the central nervous system (CNS). It is 
associated with a wide variety of neurological diagnoses. A few examples are: 
cerebrovascular accident (CVA), cerebral palsy(CP), traumatic brain injury 
(TBI), and spinal cord injury (SCI). Resulting from an upper motor neuron 
lesion,1 spasticity is defined as the hyperexcitability of the spinal stretch reflex 
resulting in a velocity-dependent increase in the tonic stretch reflex with 
exaggerated tendon jerks.2 , . 
Spasticity has both desirable and undesirabie effects. For example, it 
can be an asset to an individual as a means for movement. By the same 
token, it can become a problem if it is too severe and interferes with movement. 
The undesirable qualities of spasticity can lead to secondary physical 
complications. Consequently, it becomes necessary to control unwanted 
spasticity in an attempt to allow the individual his or her fullest potential for 
rehabilitation. 
Intervention and management of spasticity can take a variety of forms. It 
can include conservative, medical, or surgical techniques. Which type is used 
will be affected by each individual's particular needs and problems. Treatment 
1 
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is driven by symptoms because, in the majority of cases, the underlying cause 
cannot be treated or reversed (Le., traumatic brain injury).3 
The purpose of this independent study is to explore current literature and 
to discuss two medical approaches for the management of spasticity. This 
review will include an examination of spasticity, a discussion of pharmacological 
therapy, and a discussion of dorsal rhizotomy. 
CHAPTER 2 
SPASTICITY 
Spasticity is often encountered in individuals who have sustained some 
type of insult to the CNS. More specifically, the lesion can be either to the 
brain or spinal cord.3 It is important to note that this spasticity stems from an 
upper motor neuron lesion,4 such as would result with injury or pathology to the 
brain or spinal cord. 
There are a variety of neurological diagnoses in which spasticity manifests 
itself. These include traumatic brain and spinal cord injury, multiple sclerosis, 
cerebrovascular accident, cerebral palsy, and some rare degenerative 
processes of the CNS.1,3,5 
Clinically, there are a variety of other phenomena which are related to 
spasticity. These phenomena vary somewhat depending upon whether it is a 
cerebral lesion or an insult to the spinal cord.6 Spinal cord lesions present with 
flexor patterns in the lower extremities, early flexor spasms, clasp-knife 
phenomenon, clonus, spinal shock for 1-16 weeks, exaggerated exteroceptive 
reflexes, and autonomic dysreflexia.6 Cerebral lesions present with tone 
predominant in antigravity muscles, rare flexor spasms, less clasp-knife 
phenomenon, less clonus, cerebral shock for two to three weeks, absence of 
3 
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superficial abdominal and cremasteric reflexes', absent autonomic phenomena.6 
Samkoff states that when damage to the CNS occurs, it leads to a 
disconnection of the lower motor neuron from the control of upper motor 
neurons of the brain, brainstem, and spinal cord. Spasticity is only one 
manifestation of an upper motor neuron lesion, and there are associated 
positive signs such as the Babinski response, hyperactive nociceptor reflexes, 
flexor and extensor spasms, and dystonia. Weakness and loss of dexterity are 
negative signs. 
Considering the various neurological diagnoses and their site of insult, it 
becomes evident that the clinical picture of spasticity will vary from patient to 
patient. For example, consider the differences between an individual with 
multiple sclerosis and an individual who has sustained a CV A. Multiple 
sclerosis is a progressive degenerative disease in which spasticity may stem 
from the involvement of multiple sites8 ; thus, spasticity could present in more 
than one area of the body simultaneously. An individual who has sustained a 
CVA typically has had an insult of cerebral origin, with deficits occurring on the 
side of the body opposite to the site of the lesion.1 This example demonstrates 
how the physical manifestation of spasticity varies with diagnosis and the 
specific location of the lesion. 
A closer examination of the definition of. spasticity becomes necessary to 
truly gain a better knowledge of this complex phenomenon. Lance2 describes 
spasticity as the hyperexcitability of the spinal stretch reflex resulting in a 
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velocity-dependent increase in the tonic stretch reflex with exaggerated tendon 
jerks. Lance proposed this definition in 1980, and it is now widely accepted as 
the definition of spasticity by most clinicians and physiologists.9 
Young and Wiegner10 stated that "spastic patients may be more 
handicapped by reduction in reciprocal inhibition than by hyperexcitability of the 
stretch reflex." Pierrot-Deseilligny11 suggests that motor disability comes from 
the triggering of a stretch reflex in antagonistic muscles during active 
movement. An exaggeratio.n of the stretch reflex or a malfunction of reciprocal 
la inhibition are both means by which this could happen. 
Although there are different opinions about the underlying cause of 
spasticity, a similarity does exist: involvement of the stretch reflex and 
reciprocal inhibition. 
The stretch reflex begins when extrafusal (skeletal) muscle fibers are 
stretched, resulting in increased activity in the alpha motor neurons of the 
agonist muscle, causing it to contract. The afferent limb of the reflex consists 
of the type la and II afferents which run from the muscle spindle, enter the 
spinal cord, and then synapse with the alpha motor neurons of the agonist 
muscle. The la afferents also synapse with inhibitory interneurons to the 
antagonist preventing contraction (reciprocal inhibition). The stretch reflex can 
be evoked by a dynamic stretch, such as tapping the tendon, or by a static 
stretch. In this pathway is another interneuron called the Renshaw cell. It is 
stimulated each time the alpha motor neuron is activated. This activation 
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causes inhibition of the same motor neuron which activated it. It is believed 
that the Renshaw cell diminishes the activity of the alpha motor neuron to 
prevent oscillation or, in other words, continuous reflex action.12 
As physical therapists work with neurological patients, the role of 
spasticity becomes an important issue. Spasticity can be beneficial or 
problematic. Spasticity may be welcomed for the following reasons: bowel 
training, hemiplegic gait, increased muscle bulk; reduced risk of osteopenia.13 
Spasticity of sphincter muscles may provide a means by which a patient can 
develop a bowel and bladder control program. The hemiplegic patient may 
have enough muscle tone as a result of spasticity which will aid in learning to 
walk again with a leg that cguld have potentially been flaccid or weak. An 
increase in muscle tone due to spasticity may be a favorable source of stress 
on bones in preventing breakdown of bone which would result if muscular 
stresses are removed. 
Problems can arise when spasticity becomes too severe. Some of the 
negative effects which result may include: pain, impaired hygiene, joint 
contracture, hydronephrosis and renal damage, pressure ulcer formation and 
skin breakdown, and impaired activities of daily living and functional 
activities.13•14 Pain may result from severe and violent spasms. Hygiene of the 
perineal area will be limited if adductors become tight and prevent proper 
washing of that area. Joint"contracture will be a result of prolonged contracture 
which leads to insufficient movement throughout the range of motion and 
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results in contracture formation. 10 When excessive spasticity of the urinary 
sphincter exists, it may cause reflux of urine and result in problems with the 
renal system. Pressure sores and skin breakdown occur when there is an 
inability to sufficiently relieve pressure. Impaired activities of daily living and 
functional activities result when there is absence of voluntary control and 
movement. 
Physical therapists treating neurological patients will primarily be 
interested in how motor function has been affected. After all, rehabilitation of 
motor function is the area in which the physical therapist spends all of his or 
her time. Haley and Inaci014 contend that spasticity in upper motor neuron 
syndromes influences motor dysfunction in three ways. First, it affects passive 
movement and static postural alignments. Second, it affects voluntary 
movement. Third, it may coexist with other upper motor neuron deficits and 
may play an insignificant ro!~ in regard to motor dysfunction. Earlier, we 
examined specific examples of problems and benefits of spasticity. These are 
clearly related to the influence that spasticity has on motor dysfunction. These 
three factors involve the very areas addressed by physical therapy. 
Assessment becomes necessary to evaluate whether spasticity is 
interfering with movement and, if so, to what degree. When spasticity is too 
severe and interrupts motor function, it becomes necessary to implement 
management techniques in order to decrease the severity of the negative 
effects. Ideally, intervention aims at making positive gains in motor function. 
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By decreasing or negating spasticity and its effect upon motor function, it is 
thought that motor movement will become less difficult. 
Homberg 15 suggests that the rehabilitation program should be a multi-
disciplinary process involving goal setting and continual reassessments. He 
suggests a rehabilitation process in spastic syndromes. The process involves 
four steps: 1) Identify actual functional deficits; 2) Establish a plan to alleviate 
deficits and exploit residual function; 3) Before considering drugs, exploit 
residual abilities and/or physical therapy; 4) Do not use drugs without defining 
clear goals for activities of daily living. 
Although the author intended this system to evaluate the need for drug 
therapy, it clearly is a useful system when considering any type of intervention. 
It should be kept in mind that treatment should be planned based upon goals 
and desired outcome. Treatment should not simply aim at eliminating 
spasticity, but look at spasticity in terms of how it is affecting the individual's 
level of function. The overall goal should be to maximize the individual's ability 
to function in daily living. 
There are a variety of approaches for the management of spasticity. The 
physical therapist may be directly involved by using conservative physical 
therapy techniques. These may include such things as range or motion, 
therapeutic exercise, functional electrical stimulation, heat and cold modalities, 
vibration, and orthoses. 13 Other techniques include seating, splinting, and 
casting.16 However, the use of conservative management alone may not be 
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enough. It may be necessary to implement medical methods of managing 
spasticity. Prescribing medical intervention is not within the scope of physical 
therapy practice. However, the physical therapist and consequently the 
physical therapy program will be directly affected by the medical treatment of 
spasticity. Furthermore, conservative techniques and medical management 
may be combined to create a spasticity management program customized to 
the individual's needs. Barnes16 states that treatment should be based upon 
establishment of specific functional goals which are based upon the 
improvement of function, the prevention of complications, and the alleviation of 
pain. 
CHAPTER 3 
PHARMACOLOGICAL TREATMENT 
Pharmacological agents are frequently used for reducing spasticity. In 
the literature7,16-18 pharmacological agents are listed as a very relevant and 
commonly used method 0.1 intervention for spasticity. Pharmacological agents 
include oral and intrathecal administration of medications and local injections of 
various agents. 
Medications 
Several articles7,16,18 list the three most common antispastic medications 
as diazepam, dantrolene sodium, and baclofen. Though often used singly, they 
may be used in various combinations.16 This allows a cpmbination of effects 
from several drugs in attempt to gain maximal benefits. 
Diazepam, also known as Valium, has an affect both on the brain and on 
the spinal cord.7 · lt belongs to the family of benzodiazepines1•9 Taken orally, 
diazepam acts to increase inhibitory activity of lower motor neurons by 
facilitating transmission of GABA at GABAA-receptor sites. Common side 
, 
effects include drowsiness, dizziness, weakness, hypotension, fatigue, vertigo, 
ataxia, and withdrawal.7,16,18 
10 
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A study of the effects of a low dose benzodiazepine (Clonazepam) 
revealed that treatment with a low dose benzodiazepine was e,ffective in 
reducing spasticity in children with cerebral palsy.17 Young and Delwaide18 
state that Diazepam is a useful treatment approach in individuals with spinal 
cord damage and sometimes for individuals with cerebral palsy. Penn20 feels 
that it is the second most effective drug for treating spasticity next to baclofen 
and that the side effects limit its use, often before clinical relief of symptoms are 
seen. 
Dantrolene sodium is administered orally and has a direct effect on the 
muscle tissue itself?·18 It interrupts muscle contraction by suppressing the 
release of calcium from the sarcoplasmic reticulum/·20 thus interfering with the 
sequence of steps involved in a muscle contraction. 
Common side effects include drowsiness, dizziness, weakness, fatigue, 
and diarrhea.16 Barnes 16 notes that there have been reports of hepatotoxicity 
and that liver function should be closely monitored in those individuals receiving 
dantrolene. Additionally, dantrolene sodium and its action on the muscle cause 
mus9Je weakness?·2o Several authors·18.2o suggest that Dantrolene sodium may 
only be desirable for individuals who are not expected to make functional gains 
due to: the effect of muscle weakness. , , 
• Young and Delwaide18 state that dantrolene may be helpful in reducing 
spasticity regardless of where the lesion is located. This includes individuals 
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with multiple sclerosis, spinal cord injury, cerebral palsy, and cerebrovascular 
accident. 
Baclofen may be administered oralll,16,20 or intrathecally.21-23 Baclofen 
acts as an agonist to GABAs-receptors? Its action is to inhibit the release of 
excitatory neurotransmitters and it primarily targets polysynaptic spinal 
reflexes.16 The main side effects include drowsiness, fatigue, and muscle 
weakness which are usually dose-dependent effects. It has been suggested by 
several authors16,2o that baclofen may be most effective for spasticity of spinal 
origin. 
Intrathecal baclofen is administered via an infusion pump which delivers 
baclofen into the subarachnoid space.21 The pump is implanted under the skin 
on the lateral aspect of the abdomen. It is then hooked to a catheter in the 
intrathecal space. Penn20 explains the benefit of administering baclofen 
intrathecally over administering it orally. He states that the dose of oral 
baclofen required to relieve symptoms in individuals with severe spasticity will 
often cause unwanted side effects. However, if delivered directly into the 
subarachnoid space, the concentration is higher around the spinal cord while 
remaining low around the brain. Thus, unwanted side effects can be avoided 
while delivering adequate levels of baclofen to the spinal cord promoting its 
effect on spasticity. 
Several studies24',25 have shown the effectiveness of intrathecal baclofen 
for treating spasticity in cerebral palsy and other causes of cerebral origin. 
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These studies showed significant decreases in muscle tone after intrathecal 
administration of baclofen. Confusion and drowsiness occurred in two of the 
subjects of one study, but cleared two hours following the dose.24 Intrathecal 
baclofen may also be useful for long term treatment of multiple sclerosis or 
spinal cord injury.21 
Side effects from intrathecal baclofen are due to the side effects of the 
drug itself. An overdose may lead to seizures, coma, respiratory problems, and 
flaccidity.21 There may be technical difficulties with kinks, dislodging, 
disconnections, or tears in the catheter. Additionally, infection at the site of the 
pump or pump failure may occur. 
There are many other medications which have been used to decrease 
spasticity; however, they are not as common. Two recent examples include 
tizanidine7 and divalproex sodium~6 Tizanindine, an alph~-receptor agonist, is 
thought to reduce the release of the excitatory neurotransmitter, aspartate.7 
However, it is currently not available in the United States. Divalproex sodium, 
an antiepileptic agent, was shown to be an effective oral agent for improving 
pain and spasticity in three out of four patients in a recent study.26 
Local Injections 
. . 
Inclusive in this category are nerve blocks and other local injections. 
Nerve blocks involve the injection of a nerve with phenol, alcohol, or a local 
anaesthetic agent using a needle.16 Nerve blocks decrease spasticity by 
blocking nerve conduction through chemical neurolysis of nerve tissue.2728 
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Barnes 16 states that it is preferable to block motor nerves rather than mixed 
sensorimotor nerves. However, it is possible to inject either motor nerves or 
. . 
mixed sensorimotor nerves.27 Nerves which are commonly blocked include: 
obturator, sciatic, tibial, femoral, paravertebral, thoracodorsal, 
musculocutaneous, median, and ulnar.16.27 
Gunduz, et al28 conducted a study in which peripheral nerve blocks were 
used to treat spasticity in spinal cord injured patients. The results showed that 
peripheral nerve blocks were effective in relieving spasticity, but only on a 
temporary basis. 
Keenan, et al29 performed a study with percutaneous block of the 
musculocutaneous nerve to control elbow flexor spasticity. The results revealed 
that this method provides a reliable and tempqrary means for reducing 
spasticity. The authors felt it would be especially helpful in those individuals 
who have potential to improve neurologically. 
Side effects of peripheral nerve blocks are minimal. Patients may 
become anxious and need to undergo general anaesthesia or local anaesthetic 
may be applied, however, will not be effective if thE:lre is a need to penetrate 
more deeply.16 
Botulinum-A toxin, an exotoxin produced by the bacterium Clostridium 
Botulinum, is a new agent used for local intramuscular injections.30 It is injected 
directly into the muscle? The botulinum toxin blocks the presynaptic release of 
acetylcholine causing a neuromuscular block.30 · 
15 
Snowet al,31 conducted a study with nine chronic multiple sclerosis 
patients who were confined to a bed or wheelchair and were residents of a long 
term care facility. The study involved injecting the botulinum toxin into spastic 
adductors of the subjects to see if it would allow for easier nursing care. The 
results of the study revealed that there were significant improvements in muscle 
tone, frequency of spasm, and hygiene. No side effects were noted. 
In a double-blind study testing the effectiveness of botulinum-A toxin to 
manage dynamic equinus deformity associated with cerebral palsy, Koman and 
associates32 reported improvement in the gait pattern of five out of six patients. 
Although no significant side"effects were noted, soreness occurred at the site of 
injection in three of six subjects. However, this side effect also occurred with 
the placebo. 
CHAPTER 4 
DORSAL RHIZOTOMY 
Dorsal rhizotomy, more commonly referred to as selective posterior 
rhizotomy (SPR) or selective dorsal rhizotomy (SDR), is a neurosurgical 
procedure that reduces spasticity and hyperactive stretch reflexes by cutting 
through the sensory portion of selected posterior nerve rootlets in the 
lumbosacral area.33.34 They are most commonly performed on individuals with 
cerebral palsy; however, they have sometimes been used for spasticity in 
patients with myelomeningocele, multiple sclerosis; head injury and, spinal cord 
injury.33 
Surgery is performed 'with the patient under general anaesthesia and 
begins with a laminectomy or laminotomy medial to the facet joint of L2-Ls 
vertebrae. The posterior nerve roots and rootlets from L2 through ~ are 
identified and then stimulated electrically. Motor responses are monitored 
visually, by palpation, and via electromyography (EMG). Abnormal responses 
are considered to be: a duration sustained beyond the one second stimulus, 
spread of contraction to other muscles not innervated by the rootlet which was 
tested, and other irregular patterns of contraction. Those rootlets which present 
16 
17 
with abnormal responses are severed. All other rootlets are left intact.34,35 
Generally, 25% to 60% of the sensory rootlets are clipped.35 
Success of SPR relies heavily upon appropriate patient selection and a 
commitment by the family and patient to participate in an aggressive 
postoperative physical therapy program.36 Patient selection should be 
conducted by a team and may include the following disciplines: physical 
therapist, occupational ~herapist, social worker, pecjiatrician, neurophysiologist, 
orthopaedic surgeon, and surgical neurologist.36 Candidate selection is very 
crucial because it attempts to rule out those who have motor impairments due 
to dystonia, athetosis, ataxia, and abnormal reflex posturing.5 Peacock and 
Staudes list the following six factors for the selection process: 1) Confirm 
diagnosis of CP; 2) Identify spasticity as a predominant interfering factor; 
3) Rule out other forms of hypertonicity, such as rigidity and dystonia; 
4) Evaluate range of motion (ROM) - osteotendinous deformities will not be 
helped by rhizotomy; 5) Evaluate underlying strength and selective control; 
6) Goals should be carefully· considered and discussed with patient and family 
prior to surgery. 
The overall goal of patient selection is to select those individuals who 
have the potential to make some improvements from their present functional 
level.34-36 For example, a child who adducts severely during gait may have 
eased gait after the spasticity in the adductors has decreased. However, a 
child who does not have the potential to ambulate will not become ambulatory 
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simply from undergoing the surgery. In contrast, however, a child who relies on 
spasticity for movement may experience a decrease in function when that is 
taken away. Surgery can help to improve the quality and performance of skills 
that the child can already do and will heavily depend upon strength, motor 
control, absence of osteotendinous deformities, and other factors which exist 
prior to surgery.35 Selective posterior rhizotomy may be favorable to reduce 
severe spasticity in individuals to ease positioning and to inhibit formation of 
deformities.37 Several author~5,36 list characteristics desirable for SPR 
candidates (Table 1). 
Contraindications for SPR include weakness of antigravity muscles, 
weakness or hypotonia of the trunk, major non-spastic motor disorders 
(athetosis, ataxia, rigidity, dystonia), severe spinal deformity or scoliosis, 
multiple fixed contractures, multiple prior extremity surgery (with exception), and 
mentally retarded (with exception).35,36 Children who have severe spastic 
quadriplegia may be unrealistic candidates because all rootlets which are 
stimulated react abnormally and a partial rhizotomy of 60% to 70% of all 
rootlets may only provide minimal long term relief.36 
Boscarino and associates38 examined the effects of selective dorsal 
rhizotomy on the gait pattern of children who had cerebral palsy. Nineteen 
children who were ambulatory (both independent and dependent upon a 
walking aid) underwent preoperative and postoperative (one year) gait analyses 
that included assessment ·of range of motion (ROM), muscle tone, motion 
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Table 1. Desirable characteristics of selective posterior rhizotomy candidates. 
Born prematurely 
Spastic diplegic 
Age 2-10 years 
Progressive motor development history 
Evidence of selective motor control 
Good trunk control 
Good underlying strength 
Potential ambulator (preferably independent ambulator) 
Absence of fixed contractures 
Minimal or no previous lower extremity surgery 
Minimal or no osteotendinous changes 
Absence of postural hypotonia 
Motivation/commitment to postoperative physical therapy 
Intelligence (10 > 80) for effective therapy participation 
Family support 
Possibility of eased nursing care 
Prevent/stop severe joint contractures and subluxations 
20 
analysis in three dimensions, and electromyography during gait. Examiners noted 
improvements in passive ROM, lower extremitY spasticity, and sagittal plane hip, 
knee, and ankle motion. Additionally, on the average there was a greater amount 
of plantargrade foot position during stance phase. No changes were noted in 
coronal plane motion of the hip and pelvis. An increase in anterior pelvic tilt 
position in the independent .ambulators was noted as the only negative change. 
Park and colleagues39 examined how dorsal rhizotomy affects lateral hip 
migration in children with spastic diplegia. A migration percentage was calculated 
through preoperative and postoperative radiographs of the hips of 67 children. All 
children were between the ages of two and eleven at the time of surgery. Follow-
up periods ranged from six to 46 months. The migration percentages remained 
unchanged in 75%, decreased in 17%, and increased in 7% of all patients. The 
examiners felt that results suggested that lateral hip migration is halted by selective 
dorsal rhizotomy in the great majority of cases of children with spastic diplegia. 
McLaughlin and associates40 conducted an observational study of 34 
consecutive children who received SDR at their facility. Twenty-four of the children 
had spastic diplegia and ten had spastic quadriplegia. All children received one 
month of postoperative physical therapy and received physical therapy 
prescriptions in their own communities for one year. They were assessed 
preoperatively and one year after surgery. The following tools were used for 
assessment: Ashworth scale, which is a sca1e for grading spasticity; range of 
motion; deep tendon reflex responses; and the Gross Motor Function Measure, 
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which measures gross motor skills and changes in children with cerebral palsy. 
Results revealed a great deal of variability with each individual; however, often 
spasticity in the lower extremities was reduced and functional capabilities improved 
with SDR. The authors felt it necessary to conduct further studies to determine the 
effectiveness of SDR. 
None of the studies38-40 listed any major complications as a result of surgery. 
McLaughlin, et al40 report some mild complications.in a small number of children 
postsurgically, such as mild transient paresthesias lasting two weeks or less, 
dysesthesias for more than two months, postoperative bladder incontinence as a 
result of urethrities which resolved with antibiotic treatment. Additionally, some had 
reported back or hip pain for two weeks to six to nine months, intermittent mild 
back pain for approximately six months. Peacock and Staudes list the possibility 
of the following postoperative problems: hypersensitivity of the feet and legs and 
flexor spasms early following surgery; crouched posture; poor tibial control; ankle 
valgus; weakness of trunk, hip, quadriceps, calves and dorsiflexors. Yet other 
authors41 •42 list these possible temporary complications: kyphosis, wound infection 
or meningitis, cerebral spinal fluid leak, motor paralysis, transient or permanent 
sensory loss, bladder or bowel dysfunction, valgus or varus foot position, transient 
muscle weakness and hypotonia, risk from anaesthesia. 
CHAPTER 5 
CONCLUSION 
Spasticity is a very complex and intriguing phenomenon. It is an entity with 
which physical therapists are quite frequently faced. Although it may be beneficial 
in some cases, it is more commonly a major source of disability to those who have 
sustained an insult to the central nervous system. When it becomes too severe, 
it can cause multiple complications which interfere with activities of daily living. It 
is for this reason that management of spasticity becomes necessary. 
Physical therapists will frequently be directly involved in the treatment of 
individuals with spasticity, including approaches to decrease unwanted spasticity. 
However, often this will not suffice and medical management will become 
necessary. 
Medical management may include the use of pharmacological agents or 
neurosurgical techniques, such as selective dorsal rhizotomy. Pharmacological 
treatment may include medications or local inje.ctions with various agents. These 
methods are temporary and the effects only last for short periods unless use is 
continued and/or repeated. The commonly used oral medications are diazepam, 
dantrolene sodium, and baclofen. Baclofen may be administered orally as well as 
22 
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intrathecally. Local treatment includes injections with phenol, alcohol, a local 
anaesthetic agents, or the botulinum-A toxin. 
Dorsal rhizotomy may be an option for spasticity management if other 
methods have proven ineffective. Its effects are permanent and irreversible 
because nerve rootlets are actually severed. 
The particular method of management will depend upon the severity of 
spasticity and the goals to be achieved with reduction. The pros and cons of each 
method will need to be considered carefully in order to select the most appropriate 
treatment. Physical therapists may not prescribe pharmacological or surgical 
treatments; however, they may be a member of a multidisciplinary team which 
assesses and sets goals for patients. The physical therapist serves a vital role by 
contributing information as to whether or not an individual could improve 
functionally if spasticity were reduced. 
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